Lithium suppression of tau induces brain iron accumulation and neurodegeneration

[1]  Sruthi Ramagiri,et al.  Delayed neuroprotection against cerebral ischemia reperfusion injury: putative role of BDNF and GSK-3β , 2016, Journal of receptor and signal transduction research.

[2]  K. Shulman,et al.  Lithium Use in Older Adults is Associated with Increased Prescribing of Parkinson Medications. , 2016, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[3]  D. Cohen,et al.  Early interventions for youths at high risk for bipolar disorder: a developmental approach , 2016, European Child & Adolescent Psychiatry.

[4]  Shengyou Yu.  Role of nephrin in podocyte injury induced by angiotension II , 2016, Journal of receptor and signal transduction research.

[5]  Jian-Qiang Lu,et al.  Validation of quantitative susceptibility mapping with Perls' iron staining for subcortical gray matter , 2015, NeuroImage.

[6]  M. Alda,et al.  Prophylactic lithium treatment and cognitive performance in patients with a long history of bipolar illness: no simple answers in complex disease-treatment interplay , 2014, International Journal of Bipolar Disorders.

[7]  M. Ceylan,et al.  Lithium-induced cortical atrophy and cognitive dysfunction , 2014, BMJ Case Reports.

[8]  A. Bush,et al.  β-Amyloid Precursor Protein Does Not Possess Ferroxidase Activity but Does Stabilize the Cell Surface Ferrous Iron Exporter Ferroportin , 2014, PloS one.

[9]  A. Bush,et al.  Motor and cognitive deficits in aged tau knockout mice in two background strains , 2014, Molecular Neurodegeneration.

[10]  D. Kosman,et al.  sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin , 2014, EMBO reports.

[11]  E. Teng,et al.  Loss of MAP Function Leads to Hippocampal Synapse Loss and Deficits in the Morris Water Maze with Aging , 2014, The Journal of Neuroscience.

[12]  Peng Lei,et al.  Nigral Iron Elevation Is an Invariable Feature of Parkinson's Disease and Is a Sufficient Cause of Neurodegeneration , 2014, BioMed research international.

[13]  J. Milles,et al.  Cortical phase changes in Alzheimer's disease at 7T MRI: A novel imaging marker , 2014, Alzheimer's & Dementia.

[14]  Peng Lei,et al.  A delicate balance: Iron metabolism and diseases of the brain , 2013, Front. Aging Neurosci..

[15]  W. Ong,et al.  Stable iron isotope tracing reveals significant brain iron uptake in adult rats. , 2013, Metallomics : integrated biometal science.

[16]  M. Alda,et al.  Smaller hippocampal volumes in patients with bipolar disorder are masked by exposure to lithium: a meta-analysis. , 2012, Journal of psychiatry & neuroscience : JPN.

[17]  M. Portella,et al.  Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study , 2012, Psychological Medicine.

[18]  S. Ayton,et al.  The Aβ-Induced NFAT Apoptotic Pathway Is Also Activated by GSK-3 Inhibition: Implications for Alzheimer Therapeutics , 2012, The Journal of Neuroscience.

[19]  L. H. van den Berg,et al.  Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  Blaine R. Roberts,et al.  Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export , 2012, Nature Medicine.

[21]  G. Pell,et al.  Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. , 2012 .

[22]  J. Woodgett,et al.  Molecular Neuroscience Review Article , 2009 .

[23]  A. Bush,et al.  GSK-3 in Neurodegenerative Diseases , 2011, International journal of Alzheimer's disease.

[24]  H. Scholz,et al.  Phorbol-Ester Mediated Suppression of hASH1 Synthesis: Multiple Ways to Keep the Level Down , 2011, Front. Mol. Neurosci..

[25]  L. Mazzini,et al.  Disabling Parkinsonism following brief exposure to lithium carbonate in amyotrophic lateral sclerosis , 2011, Journal of Neurology.

[26]  A. Bush,et al.  Presenilins Promote the Cellular Uptake of Copper and Zinc and Maintain Copper Chaperone of SOD1-dependent Copper/Zinc Superoxide Dismutase Activity* , 2011, The Journal of Biological Chemistry.

[27]  C. Grossi,et al.  Lithium Improves Hippocampal Neurogenesis, Neuropathology and Cognitive Functions in APP Mutant Mice , 2010, PloS one.

[28]  C. Masters,et al.  Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease , 2010, Cell.

[29]  Linda Partridge,et al.  Inhibition of GSK-3 Ameliorates Aβ Pathology in an Adult-Onset Drosophila Model of Alzheimer's Disease , 2010, PLoS genetics.

[30]  J. Lucas,et al.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. , 2010, The Journal of clinical investigation.

[31]  C. Enzinger,et al.  Mapping of iron deposition in conjunction with assessment of nerve fiber tract integrity in amyotrophic lateral sclerosis , 2010, Journal of magnetic resonance imaging : JMRI.

[32]  R. Conwit,et al.  Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[33]  M. Swash.  Lithium time-to-event trial in amyotrophic lateral sclerosis stops early for futility , 2010, The Lancet Neurology.

[34]  G. Goodwin,et al.  The BALANCE trial – Authors' reply , 2010, The Lancet.

[35]  N. Inestrosa,et al.  Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer's disease , 2010, Molecular Psychiatry.

[36]  G. Goodwin,et al.  Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial , 2010, The Lancet.

[37]  M. Berk,et al.  Is Lithium in a Class of Its Own? A Brief Profile of Its Clinical Use , 2009, The Australian and New Zealand journal of psychiatry.

[38]  J. Hodges,et al.  Phosphorylation of soluble tau differs in Pick’s disease and Alzheimer’s disease brains , 2009, Journal of Neural Transmission.

[39]  Philip D. Harvey,et al.  Effects of lithium on cognitive performance: a meta-analysis. , 2009, The Journal of clinical psychiatry.

[40]  H. Möller,et al.  Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. , 2009, The Journal of clinical psychiatry.

[41]  P. Grof,et al.  A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. , 2009, Bipolar disorders.

[42]  Massimo Midiri,et al.  Improved T2* assessment in liver iron overload by magnetic resonance imaging. , 2009, Magnetic resonance imaging.

[43]  G. Cole,et al.  GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals , 2009, Neurobiology of Disease.

[44]  S. Lovestone,et al.  A feasibility and tolerability study of lithium in Alzheimer's disease , 2008, International journal of geriatric psychiatry.

[45]  F. Terro,et al.  Lithium down-regulates tau in cultured cortical neurons: A possible mechanism of neuroprotection , 2008, Neuroscience Letters.

[46]  S. Itohara,et al.  Cortical Glutamatergic Neurons Mediate the Motor Sedative Action of Diazepam , 2008, Molecular Pharmacology.

[47]  J. Lucas,et al.  Neuronal apoptosis and reversible motor deficit in dominant‐negative GSK‐3 conditional transgenic mice , 2007, The EMBO journal.

[48]  F. LaFerla,et al.  Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. , 2007, The American journal of pathology.

[49]  V. Võikar,et al.  KCC2-Deficient Mice Show Reduced Sensitivity to Diazepam, but Normal Alcohol-Induced Motor Impairment, Gaboxadol-Induced Sedation, and Neurosteroid-Induced Hypnosis , 2007, Neuropsychopharmacology.

[50]  E. Masliah,et al.  Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3β Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation , 2007, The Journal of Neuroscience.

[51]  Chuanshu Huang,et al.  Deferoxamine synergistically enhances iron-mediated AP-1 activation: A showcase of the interplay between extracellular-signal-regulated kinase and tyrosine phosphatase , 2007, Free radical research.

[52]  J. Lucas,et al.  Chronic lithium administration to FTDP‐17 tau and GSK‐3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre‐formed neurofibrillary tangles do not revert , 2006, Journal of neurochemistry.

[53]  A. Yung,et al.  Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States , 2005 .

[54]  J. Trojanowski,et al.  Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies , 2005, Acta Neuropathologica.

[55]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  F. Liu,et al.  Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. , 2004, Biochemistry.

[57]  Hok Pan Yuen,et al.  Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features , 2004, Schizophrenia Research.

[58]  P. Greengard,et al.  GSK-3-selective inhibitors derived from Tyrian purple indirubins. , 2003, Chemistry & biology.

[59]  E. Vieta,et al.  Molecular targets of lithium action , 2003, Acta Neuropsychiatrica.

[60]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[61]  Hok Pan Yuen,et al.  Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group , 2003, Schizophrenia Research.

[62]  J. Trojanowski,et al.  Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study , 2003, Acta Neuropathologica.

[63]  Jingxia Li,et al.  Role of bioavailable iron in coal dust-induced activation of activator protein-1 and nuclear factor of activated T cells: difference between Pennsylvania and Utah coal dusts. , 2002, American journal of respiratory cell and molecular biology.

[64]  P. Mazzarello,et al.  A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole , 2002, Journal of Clinical Neuroscience.

[65]  A. Takashima,et al.  Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100 , 2002, Neuroscience Letters.

[66]  H. Hofer,et al.  Redox Control of Calcineurin by Targeting the Binuclear Fe2+-Zn2+ Center at the Enzyme Active Site* , 2002, The Journal of Biological Chemistry.

[67]  M. Vitek,et al.  Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. , 2001, Journal of cell science.

[68]  J. Trojanowski,et al.  Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia , 2001, Annals of neurology.

[69]  U. Muthane,et al.  Tardive Parkinsonism, orofacial dyskinesia and akathisia following brief exposure to lithium carbonate , 2000, Journal of the Neurological Sciences.

[70]  M. Takahashi,et al.  Lithium Inhibits Neurite Growth and Tau Protein Kinase I/Glycogen Synthase Kinase‐3β‐Dependent Phosphorylation of Juvenile Tau in Cultured Hippocampal Neurons , 1999, Journal of neurochemistry.

[71]  S. Kaech,et al.  Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations , 1999, Biological Psychiatry.

[72]  C. Duyckaerts,et al.  Cerebral T2-Weighted Signal Decrease During Aging in the Mouse Lemur Primate Reflects Iron Accumulation , 1998, Neurobiology of Aging.

[73]  Virginia M. Y. Lee,et al.  Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3* , 1997, The Journal of Biological Chemistry.

[74]  J. Ávila,et al.  Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons , 1997, FEBS letters.

[75]  A. Fallgatter,et al.  Reversible neuropsychiatrische Nebenwirkungen von Lithium bei normalen Serumspiegeln Eine Fallbeschreibung , 1997, Der Nervenarzt.

[76]  C. Klee,et al.  Superoxide dismutase protects calcineurin from inactivation , 1996, Nature.

[77]  G. Dawson,et al.  β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity , 1995, Cell.

[78]  I. Grundke‐Iqbal,et al.  Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains , 1994, FEBS letters.

[79]  K. Ohtomo,et al.  Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. , 1993, Radiology.

[80]  A. Flint.  Ageing as a risk factor for lithium neurotoxicity at therapeutic serum levels , 1993, British Journal of Psychiatry.

[81]  I. Ferrier,et al.  Lithium Neurotoxicity at Normal Therapeutic Levels , 1993, British Journal of Psychiatry.

[82]  J. Atack,et al.  In Vitro and In Vivo Inhibition of Inositol Monophosphatase by the Bisphosphonate L‐690,330 , 1993, Journal of neurochemistry.

[83]  T. Iwaki,et al.  Massive accumulation of modified tau and severe depletion of normal tau characterize the cerebral cortex and white matter of Alzheimer's disease. Demonstration using the hydrated autoclaving method. , 1992, The American journal of pathology.

[84]  G. Bartzokis,et al.  MRI in tardive dyskinesia: Shortened left caudate T2 , 1990, Biological Psychiatry.

[85]  R. Henkelman,et al.  T2 values in the human brain: comparison with quantitative assays of iron and ferritin. , 1989, Radiology.

[86]  S. Yen,et al.  Immunochemical and biochemical characterization of tau proteins in normal and Alzheimer's disease brains with Alz 50 and Tau-1. , 1988, The Journal of biological chemistry.

[87]  M. Raskind,et al.  Iron pigment in the brain of a man with tardive dyskinesia. , 1985, The American journal of psychiatry.

[88]  A. Lang.  Lithium and parkinsonism , 1984, Annals of neurology.

[89]  Z. Rihmer,et al.  Parkinsonian symptoms with lithium, lithium-neuroleptic, and lithium-antidepressant treatment. , 1983, Journal of affective disorders.

[90]  J. Langston,et al.  Permanent neurological deficits due to lithium toxicity , 1983, Annals of neurology.

[91]  S. Ogston,et al.  The influence of age on lithium efficacy and side-effects in out-patients , 1983, Psychological Medicine.

[92]  S. Lavy,et al.  Parkinsonism due to lithium carbonate poisoning. , 1981, Archives of neurology.

[93]  P. Dallman,et al.  Brain iron in the rat: extremely slow turnover in normal rats may explain long-lasting effects of early iron deficiency. , 1977, The Journal of nutrition.

[94]  S. Gershon,et al.  Cogwheel rigidity related to lithium maintenance. , 1975, American Journal of Psychiatry.

[95]  S. Gershon,et al.  Effect of Lithium on Brain Dopamine , 1973, Nature.

[96]  M. Tomkiewicz,et al.  Lithium attenuates Drug-induced Hyperactivity in Rats , 1971, Nature.

[97]  S. Snyder,et al.  The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. , 1970, The American journal of psychiatry.

[98]  G. B. Frank,et al.  Effects of drugs acting alone and in combination on the motor activity of intact mice , 1970, British journal of pharmacology.

[99]  P. Tomlin,et al.  Interdisciplinary Study of Diazepam Sedation for Outpatient Dentistry , 1970, British medical journal.

[100]  J. Cade.  Lithium salts in the treatment of psychotic excitement. , 1949, The Medical journal of Australia.

[101]  A. Bush,et al.  Biometals and Their Therapeutic Implications in Alzheimer’s Disease , 2014, Neurotherapeutics.

[102]  L. Buée,et al.  Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. , 2010, Journal of Alzheimer's disease : JAD.

[103]  M. Dziedzicka-Wasylewska,et al.  Adaptive changes in the rat dopaminergic transmission following repeated lithium administration , 2005, Journal of Neural Transmission.

[104]  S. Wood,et al.  Incipient neurovulnerability and neuroprotection in early psychosis. , 2003, Psychopharmacology bulletin.

[105]  Christina A. Wilson,et al.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. , 2003, Nature.

[106]  Jesús Avila,et al.  Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. , 2003, Journal of Alzheimer's disease : JAD.

[107]  A. Fallgatter,et al.  [Reversible neuropsychiatric side effects of lithium with normal serum levels. A case report]. , 1997, Der Nervenarzt.

[108]  G. Chouinard,et al.  A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. , 1996, The Journal of clinical psychiatry.